Sorafenib
Small molecule targets BRAF, CYP3A4, FLT3, JAK2, KIT, RAF1, RET via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | NEXAVAR | — | 2007-11-16 – 2017-12-22 | fda.gov ↗ |
| Approved | EU (EMA) | Nexavar | — | 2006-07-19 | europa.eu ↗ |
| Approved | US (FDA) | NEXAVAR | — | 2005-12-01 | fda.gov ↗ |
Trials 560 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06797427 | Feb → Mar 2025 | — | Disruptive Pharma | Completed | No outcome recorded |
| Phase 0 | NCT03965546 | May 2019 → Jun 2021 | hepatocellular carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 0 | NCT01337492 | Sep 2010 → May 2011 | hepatocellular carcinoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT00405366 | Nov 2006 → Jun 2009 | kidney cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1137 trials | ||||||
| Phase 1 | NCT06474663 | Jul 2025 | refractory hematologic cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT03132454 | Jul 2017 → Dec 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02988440 | Apr 2017 → Feb 2020 | hepatocellular carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02716012 | Mar 2016 → Jul 2025 | hepatocellular carcinoma | Mina Alpha Limited | Unknown | No outcome recorded |
| Phase 1 | NCT02779283 | Jan 2016 → Apr 2018 | acute lymphoblastic leukemia, acute myeloid leukemia | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02642913 | Dec 2015 → Mar 2021 | hepatocellular carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02538393 | Nov 2015 → Mar 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02298348 | Oct 2015 → Dec 2026 expected | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02636426 | Sep 2015 → Dec 2017 | neoplasm | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Show all 137 trials opens the full record — a long page | ||||||
| Phase 1/262 trials | ||||||
| Phase 1/2 | NCT06527495 | Jan 2023 → Dec 2024 overdue | hepatocellular carcinoma | Assiut University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05468359 | Nov 2022 → Jun 2032 expected | childhood malignant neoplasm, fibrolamellar hepatocellular carcinoma, refractory malignant neoplasm | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04069949 | Dec 2019 → Oct 2020 | hepatocellular carcinoma, portal vein thrombosis | Sichuan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04926532 | Aug 2019 → Oct 2021 | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03563170 | May 2018 → Aug 2019 | hepatocellular carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03211416 | Dec 2017 → Mar 2023 | adult hepatocellular carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT03247088 | Jul 2017 → Dec 2027 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02728050 | Dec 2016 → Feb 2022 | acute biphenotypic leukemia, myelodysplastic syndrome | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT02530476 | Dec 2015 → Apr 2019 | acute myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02227914 | Dec 2014 → Mar 2015 | hepatocellular carcinoma | Amgen | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02024087 | Aug 2014 → Jul 2017 | adult hepatocellular carcinoma | Acceleron Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01988493 | Jan 2014 → Feb 2018 | hepatocellular carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/2 | NCT02400788 | Apr 2013 → Jun 2016 | hepatocellular carcinoma | Yakult Honsha Co., LTD | Completed | No outcome recorded |
| Phase 1/2 | NCT01434602 | Oct 2012 → Oct 2020 | brain neoplasm, glioblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01534260 | Feb 2012 → Aug 2016 | acute myeloid leukemia | Hamid Sayar | Completed | No outcome recorded |
| Phase 1/2 | NCT01335074 | Apr 2011 → Dec 2013 | hepatocellular carcinoma | Philipps University Marburg | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01306058 | Feb 2011 → Jun 2016 | hepatocellular adenoma, hepatocellular carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01254890 | Jan 2011 → Mar 2015 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00999843 | Oct 2009 → Oct 2010 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00955721 | Aug 2009 → Jul 2014 | cholangiocarcinoma, gallbladder cancer | University of Miami | Terminated | No outcome recorded |
| Phase 1/2 | NCT00971126 | Jul 2009 → Jan 2010 | hepatocellular carcinoma | National Health Research Institutes, Taiwan | Terminated | No outcome recorded |
| Phase 1/2 | NCT00867321 | Apr 2009 → Apr 2012 | liver cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT00864032 | Mar 2009 → Aug 2011 | soft tissue sarcoma | University of California, Davis | Completed | No outcome recorded |
| Phase 1/2 | NCT00862082 | Mar 2009 → Jan 2010 | hepatocellular carcinoma | Proacta, Incorporated | Terminated | No outcome recorded |
| Phase 1/2 | NCT00869570 | Mar 2009 → May 2013 | colorectal cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00825734 | Mar 2009 → Jun 2013 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01226056 | Mar 2009 → Sep 2012 | cancer | Southern Europe New Drug Organization | Suspended | No outcome recorded |
| Phase 1/2 | NCT00882869 | Mar 2009 → Mar 2011 | hepatocellular carcinoma | Aegera Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT00989469 | Feb 2009 → Feb 2011 | colorectal cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 1/2 | NCT00785226 | Nov 2008 → Apr 2012 | — | Bayer | Completed | No outcome recorded |
| Phase 1/2 | NCT00828074 | Nov 2008 → Apr 2014 | female breast carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00892424 | Nov 2008 → Sep 2020 | cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/2 | NCT00791544 | Nov 2008 → Nov 2009 | liver cancer | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT00768937 | Sep 2008 → Oct 2010 | hepatocellular carcinoma | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1/2 | NCT00924807 | Sep 2008 → Dec 2013 | prostate cancer | Beth Israel Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00634634 | Aug 2008 → Apr 2019 | breast cancer | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 1/2 | NCT00712790 | Jun 2008 → Jun 2009 | hepatocellular carcinoma | Singapore Clinical Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00634751 | Feb 2008 → Jul 2010 | bile duct cancer, malignant pancreatic neoplasm | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1/2 | NCT00815295 | Jan 2008 → Jul 2013 | squamous cell carcinoma | Duke University | Completed | No outcome recorded |
| Phase 1/2 | NCT00609934 | Dec 2007 → Oct 2014 | renal cell carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/2 | NCT00536575 | Nov 2007 → Feb 2010 | plasma cell myeloma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00565370 | Nov 2007 → Dec 2009 | gastric cancer | Asan Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00764972 | Oct 2007 → Dec 2010 | breast cancer | McGill University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00541840 | Oct 2007 → Apr 2009 | soft tissue sarcoma | Spanish Group for Research in Sarcomas | Unknown | No outcome recorded |
| Phase 1/2 | NCT00542971 | Oct 2007 → May 2011 | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00526799 | Sep 2007 → Jan 2010 | ovarian cancer | Daniela Matei, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT00474929 | Aug 2007 → Nov 2011 | plasma cell neoplasm | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00547443 | Jul 2007 → Jul 2009 | lung cancer | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00417248 | Jun 2007 → Apr 2008 | non-small cell lung carcinoma | Nasser Hanna, M.D. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00510250 | Jun 2007 → Sep 2010 | cervical cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/2 | NCT00811759 | Jun 2007 → May 2009 | cutaneous melanoma | Gustave Roussy, Cancer Campus, Grand Paris | Unknown | No outcome recorded |
| Phase 1/2 | NCT00538005 | May 2007 → Jul 2009 | cutaneous melanoma | San Diego Pacific Oncology & Hematology Associates | Unknown | No outcome recorded |
| Phase 1/2 | NCT00448149 | Dec 2006 → Jun 2009 | renal cell carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00392821 | Dec 2006 → Oct 2013 | kidney cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00414388 | Dec 2006 → Sep 2011 | prostate cancer | Oncology Specialists, S.C. | Completed | No outcome recorded |
| Phase 1/2 | NCT00389285 | Oct 2006 → May 2009 | renal cell carcinoma | ZymoGenetics | Completed | No outcome recorded |
| Phase 1/2 | NCT01445080 | May 2006 → Mar 2012 | acute promyelocytic leukemia, childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, chronic myeloid leukemia +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00335764 | Apr 2006 → Feb 2010 | adult glioblastoma, giant cell glioblastoma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00329719 | Mar 2006 → Feb 2013 | adult glioblastoma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00121251 | Jun 2005 → Mar 2017 | renal cell adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00217399 | Jun 2005 → Jul 2009 | female breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00126503 | May 2005 → Oct 2011 | chromophobe renal cell carcinoma, clear cell renal carcinoma, papillary renal cell carcinoma, sarcomatoid renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2274 trials | ||||||
| Phase 2 | NCT07463248 | Mar 2026 → Jan 2028 expected | hepatocellular carcinoma | Wang Xin | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06227221 | Feb 2026 → Oct 2028 expected | type 1 diabetes mellitus | Second Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05669339 | Dec 2024 → Apr 2027 expected | hepatocellular carcinoma | University of Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT06309485 | Jul 2024 → Dec 2026 expected | hepatocellular carcinoma | Zhejiang Haichang Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06532084 | May 2024 → May 2027 expected | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | St. Petersburg State Pavlov Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06320301 | Apr 2024 → Feb 2026 | biliary tract cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT06221683 | Jan 2024 → Dec 2028 expected | childhood acute myeloid leukemia | Children's Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT06041490 | Sep 2023 → Jun 2026 overdue | hepatocellular carcinoma, osteosarcoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05873244 | Aug 2023 → Dec 2027 expected | hepatocellular carcinoma | Stephen Chan Lam | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05594095 | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Show all 274 trials opens the full record — a long page | ||||||
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07264010 | Dec 2025 → Dec 2026 expected | acute myeloid leukemia | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06972641 | Jun 2025 → Mar 2030 expected | acute myeloid leukemia, myelodysplastic syndrome | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05313958 | Dec 2021 → Mar 2026 | acute monocytic leukemia, childhood acute myeloid leukemia | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04674345 | Dec 2020 → Dec 2022 | acute leukemia | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02474290 | Jun 2015 → Jul 2018 | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT01932385 | Aug 2013 → Jan 2016 | liver cancer | Qingdao Central Hospital | Completed | No outcome recorded |
| Phase 347 trials | ||||||
| Phase 3 | NCT07203352 | Oct 2025 → Dec 2026 expected | acute lymphoblastic leukemia | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT06841172 | Jul 2025 → Jul 2027 expected | hepatocellular carcinoma | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT04770896 | Apr 2021 → Jun 2026 overdue | hepatocellular carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04229355 | Feb 2021 → Dec 2022 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04103398 | Oct 2019 → Dec 2023 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT04143191 | Sep 2019 → Sep 2021 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03533582 | May 2018 → Dec 2026 expected | fibrolamellar hepatocellular carcinoma, hepatoblastoma, pediatric hepatocellular carcinoma | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02971696 | Dec 2016 → Nov 2017 | hepatocellular carcinoma | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT02867280 | Jun 2016 → Aug 2019 | hepatocellular carcinoma | Sun Yat-sen University | Terminated | No outcome recorded |
| Phase 3 | NCT02774187 | May 2016 → Jul 2017 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02562755 | Oct 2015 → Jul 2020 | hepatocellular carcinoma | SillaJen, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02066181 | Mar 2014 → Jul 2019 | desmoid tumor | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01906216 | Sep 2013 → Jun 2022 | hepatocellular carcinoma | Air Force Military Medical University, China | Completed | No outcome recorded |
| Phase 3 | NCT01730937 | Apr 2013 → Jul 2022 | adult hepatocellular carcinoma | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT01613846 | May 2012 → Oct 2016 | renal cell carcinoma | Technical University of Munich | Completed | No outcome recorded |
| Phase 3 | NCT01371981 | Jul 2011 → Mar 2019 | myeloid sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01245582 | Jul 2011 → Feb 2014 | hepatocellular carcinoma | Sanofi | Withdrawn | No outcome recorded |
| Phase 3 | NCT01405573 | Jul 2011 → Mar 2017 | adult hepatocellular carcinoma | National Cancer Institute, Naples | Terminated | No outcome recorded |
| Phase 3 | NCT01234337 | Feb 2011 → May 2014 | female breast carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01324076 | Nov 2010 → Nov 2014 | liver cancer | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT01076010 | Mar 2010 → Jul 2014 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01015833 | Feb 2010 → May 2015 | adult hepatocellular carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01075555 | Feb 2010 → Sep 2015 | liver cancer | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 3 | NCT01004978 | Oct 2009 → Feb 2021 | hepatocellular carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00984282 | Oct 2009 → Aug 2012 | thyroid tumor | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00901901 | May 2009 → Apr 2012 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00863746 | Apr 2009 → Mar 2012 | non-small cell lung carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00732914 | Jan 2009 → Oct 2013 | renal cell carcinoma | Sponsor GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00692770 | Aug 2008 → Nov 2013 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00625378 | Dec 2007 → Sep 2021 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00474786 | Sep 2007 → Jan 2012 | renal cell carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00558636 | Sep 2007 → May 2008 | non-small cell lung carcinoma | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT00492258 | Jun 2007 → Aug 2012 | kidney cancer | Medical Research Council | Completed | No outcome recorded |
| Phase 3 | NCT00478114 | May 2007 → Aug 2009 | renal cell carcinoma | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT00449033 | Feb 2007 → Apr 2010 | non-small cell lung carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00541021 | Dec 2006 → Dec 2010 | malignant pancreatic neoplasm | Institut Paoli-Calmettes | Unknown | No outcome recorded |
| Phase 3 | NCT00326898 | Apr 2006 → Aug 2015 | clear cell renal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00494299 | Apr 2006 → Jul 2009 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00300885 | Feb 2006 → Oct 2007 | non-small cell lung carcinoma | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT00586105 | Dec 2005 → May 2008 | renal cell carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00492986 | Oct 2005 → Nov 2008 | renal cell carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00492752 | Oct 2005 → Mar 2007 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00111020 | Jun 2005 → Jun 2007 | renal cell carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00110019 | Jun 2005 → Jan 2011 | cutaneous melanoma, metastatic melanoma, mucosal melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00111007 | May 2005 → Sep 2006 | melanoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00105443 | Mar 2005 → Nov 2008 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00073307 | Nov 2003 → Sep 2006 | renal cell carcinoma | Bayer | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT05113290 | Dec 2021 → Dec 2023 | hepatocellular carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT02504983 | Aug 2015 → Jul 2021 | hepatocellular carcinoma | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02733809 | Jan 2014 → Dec 2024 | hepatocellular carcinoma | King Saud University | Unknown | No outcome recorded |
| Phase 4 | NCT01849588 | May 2013 → Dec 2016 | hepatocellular carcinoma | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT03518502 | Mar 2012 → Feb 2020 | hepatocellular carcinoma, metastatic neoplasm | Korea University | Unknown | No outcome recorded |
| Phase 4 | NCT01409499 | Jan 2011 → Jun 2017 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT01203787 | Dec 2010 → Jan 2014 | hepatocellular carcinoma | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT01098760 | Aug 2010 → Mar 2013 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00352859 | Aug → Nov 2006 | renal cell carcinoma | Bayer | Terminated | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT06030895 | Dec 2022 → Feb 2024 | hepatocellular carcinoma | Damanhour University | Completed | No outcome recorded |
| — | NCT05391867 | Jan → Dec 2022 | hepatocellular carcinoma | Sir Salimullah Medical College Mitford Hospital | Unknown | No outcome recorded |
| — | NCT03097848 | May 2017 → Dec 2018 | hepatocellular carcinoma | Southwest Hospital, China | Unknown | No outcome recorded |
| — | NCT02691780 | Dec 2016 → Dec 2018 | refractory malignant neoplasm | Samsung Medical Center | Withdrawn | No outcome recorded |
| — | NCT02450149 | May → Aug 2016 | refractory malignant neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT05063058 | Jan 2016 → Nov 2019 | melanoma | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02529761 | Aug 2015 → Aug 2021 | hepatocellular carcinoma | Air Force Military Medical University, China | Unknown | No outcome recorded |
| — | NCT02537158 | Aug 2015 → Jul 2018 | hepatocellular carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| — | NCT02015728 | Dec 2013 → Nov 2016 | brain cancer | Seattle Children's Hospital | Unknown | No outcome recorded |
| — | NCT02013089 | Dec 2013 → May 2017 | digestive system cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT02072486 | Nov 2013 → Jul 2019 | adult hepatocellular carcinoma, pediatric hepatocellular carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| — | NCT01636908 | Aug 2011 → Jan 2018 | cancer | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01190241 | Aug 2010 → Dec 2017 | cancer, metastatic neoplasm | Amsterdam UMC, location VUmc | Terminated | No outcome recorded |
| — | NCT01005875 | Nov 2009 → Dec 2012 | hepatocellular carcinoma | University of Alabama at Birmingham | Terminated | No outcome recorded |
| — | NCT00964743 | Aug 2009 → Feb 2011 | neoplastic meningitis | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| — | NCT00727532 | Jul 2008 → Oct 2011 | hereditary clear cell renal cell carcinoma | Northwestern University | Terminated | No outcome recorded |
| — | NCT00602862 | Jul 2007 → Apr 2012 | clear cell renal carcinoma | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00544167 | May 2007 → Jan 2008 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| — | NCT00619242 | Jun 2006 → Sep 2009 | esophageal cancer | University of Chicago | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02209441 | — | gastric cancer | Chinese Academy of Medical Sciences | Available | No outcome recorded |
Also used as a comparator or background therapy in 127 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 118 trials | ||||||
| Phase 1 | NCT06363006 Background | Mar 2024 → Jan 2026 overdue | hepatocellular carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05967377 Comparator | Nov 2018 → Feb 2019 | — | Xspray Pharma AB | Completed | No outcome recorded |
| Phase 1 | NCT03674060 Comparator | Oct 2018 → Feb 2019 | — | Samyang Biopharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03406364 Background | Jun 2018 → Jan 2020 | cancer | Metagone Biotech Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02989870 Background | Mar 2017 → Oct 2018 | hepatocellular carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT02423239 Background | Apr 2015 → Dec 2016 | hepatocellular carcinoma, malignant exocrine pancreas neoplasm | e-Therapeutics PLC | Unknown | No outcome recorded |
| Phase 1 | NCT02354898 Background | Mar 2015 → Oct 2018 | hepatocellular carcinoma | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02412475 Background | Feb 2015 → Jun 2017 | acute myeloid leukemia | Michael Burke | Terminated | No outcome recorded |
| Phase 1 | NCT02358395 Background | Feb 2015 → Nov 2017 | hepatocellular carcinoma | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02143401 Background | Jan 2015 → Nov 2022 | cirrhosis of liver, hepatitis B virus infection, hepatitis C virus infection, hepatocellular carcinoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02240433 Background | Nov 2014 → Jul 2017 | hepatocellular carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02069145 Background | Jan 2014 → May 2017 | hepatocellular carcinoma | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01131689 Background | Sep 2009 → Sep 2010 | hepatocellular carcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00956436 Background | Aug 2009 → Apr 2011 | hepatocellular carcinoma | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00873002 Comparator | Mar 2009 → May 2010 | liver cancer | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00823290 Background | Jan 2009 → Dec 2010 | hepatocellular carcinoma | University of Erlangen-Nürnberg Medical School | Terminated | No outcome recorded |
| Phase 1 | NCT00712855 Background | Jun 2008 → Aug 2011 | hepatocellular carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00613145 Comparator | Feb 2008 → May 2009 | refractory malignant neoplasm | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT03645980 Background | Oct 2018 → Aug 2021 | hepatocellular carcinoma | Johannes Gutenberg University Mainz | Unknown | No outcome recorded |
| Phase 1/2 | NCT02560779 Background | Nov 2016 → Aug 2019 | hepatocellular carcinoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02575339 Comparator | Jul 2016 → Jun 2018 | hepatocellular carcinoma | Kathy Miller | Terminated | No outcome recorded |
| Phase 1/2 | NCT02279719 Background | Dec 2014 → Jul 2019 | hepatocellular carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01658878 Comparator | Oct 2012 → Nov 2024 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01754987 Background | Sep 2012 → Jan 2016 | hepatocellular carcinoma | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1/2 | NCT01271504 Comparator | Jul 2011 → Jun 2015 | hepatocellular carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01258608 Background | Feb 2011 → May 2013 | hepatocellular carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT01264705 Background | Jan 2011 → Apr 2018 | hepatocellular carcinoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01178411 Background | Aug 2010 → Jan 2019 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01029418 Background | Nov 2009 → Feb 2014 | hepatocellular carcinoma | National Cancer Centre, Singapore | Terminated | No outcome recorded |
| Phase 1/2 | NCT00933816 Background | Jul 2009 → Oct 2010 | hepatocellular carcinoma | Kindai University | Completed | No outcome recorded |
| Phase 1/2 | NCT00473486 Comparator | May 2007 → Aug 2008 | non-small cell lung carcinoma | University Hospital Muenster | Terminated | No outcome recorded |
| Phase 236 trials | ||||||
| Phase 2 | NCT06690697 Comparator | Jun 2024 → Jun 2026 overdue | clear cell renal carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05822752 Comparator | Sep 2023 → Nov 2026 expected | hepatocellular carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05673824 Background | Jan 2023 → Sep 2025 | poisoning | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT04000737 Background | Jan 2020 → Mar 2024 | hepatocellular carcinoma | Yiviva Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04135690 Comparator | Oct 2019 → Dec 2023 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03780634 Comparator | Apr 2019 → Dec 2020 | hepatocellular carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03812783 Background | Nov 2018 → Dec 2019 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03477175 Background | Aug 2018 → Dec 2023 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03812770 Background | Aug 2018 → Sep 2019 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03722498 Comparator | Jun 2018 → Mar 2021 | hepatocellular carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03164057 Background | Jun 2017 → Sep 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02672488 Background | Dec 2015 → Dec 2017 | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01171482 Comparator | Nov 2015 → Apr 2016 | hepatocellular carcinoma | Seoul National University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02559778 Comparator | Sep 2015 → Sep 2030 expected | neuroblastoma | Giselle Sholler | Recruiting | No outcome recorded |
| Phase 2 | NCT02187302 Comparator | Jul 2014 → Jul 2016 | renal cell carcinoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01946529 Comparator | Dec 2013 → Aug 2015 overdue | Ewing sarcoma, desmoplastic small round cell tumor | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01703910 Comparator | Nov 2012 | colon adenocarcinoma, metastatic neoplasm, rectum adenocarcinoma | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT01480817 Comparator | Jun 2012 → Dec 2015 | hepatocellular carcinoma | Seoul National University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01539018 Comparator | Jan 2012 → Jan 2015 | hepatocellular carcinoma | Egyptian Society of Liver Cancer | Terminated | No outcome recorded |
| Phase 2 | NCT01334710 Background | Mar → Aug 2011 | liver cancer | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01272557 Comparator | Dec 2010 → Sep 2014 | liver cancer | PD Dr. med. Matthias Dollinger | Unknown | No outcome recorded |
| Phase 2 | NCT01265576 Background | Dec 2010 → Feb 2014 | hepatocellular carcinoma | Vicus Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT01004003 Comparator | Oct 2009 → Jul 2014 | hepatocellular carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00987935 Comparator | Oct 2009 → Jul 2014 | hepatocellular carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00872014 Background | Aug 2009 → Oct 2011 | hepatocellular carcinoma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT01171651 Background | May 2009 → Sep 2012 | hepatocellular carcinoma | Jennerex Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00906373 Comparator | May 2009 → Oct 2012 | hepatocellular carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00881751 Comparator | Mar 2009 → May 2016 | liver cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00618384 Comparator | Jan 2008 → May 2011 | hepatocellular carcinoma | Heinrich-Heine University, Duesseldorf | Terminated | No outcome recorded |
| Phase 2 | NCT00557830 Comparator | Jan 2008 → Apr 2011 | renal cell carcinoma | Accelerated Community Oncology Research Network | Terminated | No outcome recorded |
| Phase 2 | NCT00493636 Comparator | Jun 2007 → Sep 2010 | breast cancer | Accelerated Community Oncology Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00467025 Background | May 2007 → Apr 2010 | clear cell renal carcinoma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT01215266 Comparator | Oct 2006 → Jun 2011 | urinary bladder cancer | Association of Urologic Oncology (AUO) | Terminated | No outcome recorded |
| Phase 2 | NCT00390611 Comparator | Oct 2006 → Jul 2012 | ovarian cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00373373 Comparator | Sep 2006 → Jul 2009 | acute myeloid leukemia | University Hospital Muenster | Completed | No outcome recorded |
| Phase 2 | NCT00602576 Background | Jan 2005 → Dec 2008 | cutaneous melanoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT05033522 Comparator | Aug 2023 → Nov 2026 | hepatocellular carcinoma | Mirror Biologics, Inc. | Suspended | No outcome recorded |
| Phase 2/3 | NCT04560894 Comparator | Nov 2020 → Apr 2024 | hepatocellular carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT03794440 Comparator | Feb 2019 → Dec 2022 | hepatocellular carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT02645981 Comparator | Mar 2016 → Nov 2019 | hepatocellular carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Completed | No outcome recorded |
| Phase 2/3 | NCT02794337 Background | Dec 2014 → Jan 2024 | hepatocellular carcinoma | Tata Memorial Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02220088 Comparator | Dec 2014 → Jul 2018 | hepatocellular carcinoma | Sun Yat-sen University | Terminated | No outcome recorded |
| Phase 2/3 | NCT01901692 Comparator | Jul 2013 → Jan 2017 | hepatocellular carcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT01747642 Comparator | Dec 2012 → Dec 2013 | — | Clinical Research Organization, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 342 trials | ||||||
| Phase 3 | NCT07463651 Comparator | May 2026 → May 2028 expected | acute myeloid leukemia, FLT3 internal tandem duplication, disease related to hematopoietic stem cell transplant | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 3 | NCT04465734 Comparator | Nov 2022 → Oct 2023 | hepatocellular carcinoma | Shanghai Henlius Biotech | Withdrawn | No outcome recorded |
| Phase 3 | NCT04985136 Comparator | Sep → Dec 2021 | hepatocellular carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04709380 Comparator | Mar 2021 → Dec 2024 | hepatocellular carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT04720716 Comparator | Feb 2021 → Dec 2025 | hepatocellular carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04687163 Background | Dec 2020 → Dec 2022 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT04723004 Comparator | Oct 2020 → May 2024 | hepatocellular carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04344158 Comparator | Aug 2020 → Dec 2026 expected | hepatocellular carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04387695 Comparator | Apr 2020 → Aug 2023 | hepatocellular carcinoma, portal vein thrombosis | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT04163237 Background | Dec 2019 → Oct 2020 | liver cancer | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04039607 Comparator | Sep 2019 → Jul 2026 overdue | hepatocellular carcinoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03764293 Comparator | Jun 2019 → Feb 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02436902 Comparator | Feb 2019 → Aug 2022 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03775395 Comparator | Dec 2018 → Dec 2021 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03755791 Comparator | Jun 2018 → Nov 2021 overdue | hepatocellular carcinoma | Exelixis | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03434379 Comparator | Mar 2018 → Aug 2020 | hepatocellular carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03468231 Background | Mar 2018 → Sep 2019 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03412773 Comparator | Dec 2017 → Jul 2022 | hepatocellular carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03298451 Comparator | Oct 2017 → Aug 2021 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03236649 Comparator | Sep 2017 → Feb 2022 | hepatocellular carcinoma | Beijing Shenogen Biomedical Co., Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT03017326 Comparator | Aug 2017 → Dec 2026 expected | hepatoblastoma | University of Birmingham | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03164382 Comparator | Mar 2017 → Oct 2020 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02856126 Background | Aug 2016 → Oct 2020 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02665065 Comparator | Jun 2016 → Jun 2022 overdue | acute myeloid leukemia | Actinium Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02627963 Comparator | May 2016 → Oct 2018 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02576509 Comparator | Dec 2015 → May 2019 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02460991 Comparator | Nov 2015 → Jun 2017 | hepatocellular carcinoma | Boston Scientific Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01887717 Comparator | Feb 2014 → May 2017 | hepatocellular carcinoma | Boston Scientific Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01761266 Comparator | Mar 2013 → Nov 2016 | hepatocellular carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01482442 Comparator | Dec 2011 → Apr 2016 | liver cancer | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01223027 Comparator | Mar 2011 → Jun 2014 | clear cell renal carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01214343 Comparator | Oct 2010 → Sep 2013 | hepatocellular carcinoma | Ministry of Health, Labour and Welfare, Japan | Unknown | No outcome recorded |
| Phase 3 | NCT01135056 Comparator | Jul 2010 → Jul 2018 | hepatocellular carcinoma | Singapore General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01903694 Comparator | Mar 2010 → Nov 2013 | hepatocellular carcinoma | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
| Phase 3 | NCT01481870 Comparator | Jan 2010 → Jul 2013 | renal cell carcinoma | Yamagata University | Unknown | No outcome recorded |
| Phase 3 | NCT01009593 Comparator | Jan 2010 → Jul 2012 | hepatocellular carcinoma | Abbott | Terminated | No outcome recorded |
| Phase 3 | NCT01030783 Comparator | Dec 2009 → Jul 2012 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00920816 Comparator | Aug 2009 → Jul 2012 | kidney neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00858871 Comparator | May 2009 → Jun 2012 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00678392 Comparator | Sep 2008 → Aug 2010 | renal carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00699374 Comparator | Jul 2008 → Dec 2011 | hepatocellular carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00606866 Comparator | Jul 2004 → Jan 2007 | renal cell carcinoma | University of Chicago | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT04127396 Comparator | Sep 2019 → Aug 2021 | hepatocellular carcinoma, portal vein thrombosis | Beijing Ditan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03178656 Comparator | Dec 2016 → Apr 2018 | portal vein thrombosis | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 4 | NCT03212625 Background | Jan 2016 → Sep 2018 | hepatocellular carcinoma | Korea University Guro Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02961998 Background | Jul 2015 → Jul 2016 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07117422 Background | Jan 2025 → Jan 2026 overdue | acute myeloid leukemia | The Second Hospital of Hebei Medical University | Recruiting | No outcome recorded |
| — | NCT03730675 Comparator | Nov 2018 → Nov 2021 | hepatocellular carcinoma, portal vein thrombosis | Zhongda Hospital | Unknown | No outcome recorded |
| — | NCT05121571 Comparator | Apr 2016 → Dec 2018 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT02748304 Comparator | Apr 2016 → Feb 2019 | hepatocellular carcinoma | Fudan University | Terminated | No outcome recorded |
| — | NCT02259647 Background | Oct 2014 → Oct 2015 | hepatocellular carcinoma | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01141478 Comparator | Sep 2010 → Dec 2014 | hepatocellular carcinoma | Loma Linda University | Terminated | No outcome recorded |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 697 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sorafenib | “Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the...” NCT01178411 ↗658“combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗ “The first-line targeted-immunotherapy regimens consisted of tislelizumab combined with one of the first-line evidence-based tyrosine kinase inhibitors (TKIs), including...” NCT07463248 ↗ “Standardized FDG-PET/CT was performed at baseline and after the first cycle of combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m²/day...” PMID 26421426 ↗ Sep 2015 “TKI (Sorafenib 400mg, bid, po or Lenvatinib 8mg, qd, po if bodyweight less than 60 kg,12mg, qd, po if bodyweight more than 60kg or Donafenib：200mg, bid, po) +...” NCT06041490 ↗ “Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib.” NCT05673824 ↗ “Sorafenib is a drug that has been approved to treat kidney and liver cancer (hepatocellular carcinoma, or HCC) and has been shown to prolong survival in patients with HCC.” NCT01306058 ↗ “The objective of the study is to compare the pharmacokinetics (PK) of sorafenib after the administration of 100 mg DPH001 vs. after the administration of 200 mg Nexavar®.” NCT06797427 ↗ “Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2).” PMID 28950297 ↗ Nov 2017 “Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Sorafenib. Tab. Sorafenib will be given at doses of 200 mg 12 hourly.” NCT05391867 ↗ “High-risk group：Chemotherapy with the C-CD+ICE+ sorafenib regimen for 3 to 5 courses was followed by elective surgery, with a total of 6 to 7 courses” NCT07300449 ↗ “subjects with molecular typing of FLT3-ITD positive were to receive chemotherapy combined with sorafenib 400mg orally twice a day” NCT07203352 ↗ “sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight \<60 kg)” NCT04687163 ↗ “Sorafenib: 0.4g (2 × 0.2g) twice or once daily on an empty stomach or with a low-fat or medium-fat diet” NCT06320301 ↗ “combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio.” NCT04752527 ↗ “Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma” NCT02298348 ↗ “Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent)” NCT02665065 ↗ “A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.” PMID 28341759 ↗ Mar 2017 “Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers” NCT00398814 ↗ “BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors” NCT00095459 ↗ “Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor” NCT03406364 ↗ “sorafenib combined with realgar-indigo naturalis formula” NCT04232722 ↗ “Sorafenib (S), a multitargeted tyrosine kinase inhibitor” PMID 26884590 ↗ Feb 2016 “Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing” NCT00498836 ↗ “Drug: Everolimus Drug: Sorafenib Drug: Crizotinib” NCT03768375 ↗ “Sorafenib is multiple tyrosine kinase inhibitor.” NCT03212625 ↗ “RAS Inhibitor (Sorafenib 400 mg 2/d)” NCT05063058 ↗ “Ruxolitinib, Sorafenib, Streptozocin” NCT02788201 ↗ “Sorafenib or Gilteritinib, Day 8-14” NCT07117422 ↗ “Sunitinib, Sorafenib or Pazopanib” NCT01731158 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00661180 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00562913 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00110344 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00657254 ↗ “Ruxolitinib Sorafenib Sunitinib” NCT02551718 ↗ “sorafenib tosylate (sorafenib)” NCT01664182 ↗ “Sorafenib 400mg, PO, BID” NCT06363006 ↗ “BAY 43-9006 (Sorafenib)” NCT00098254 ↗ “400 mg of Sorafenib” NCT01337492 ↗ “Drug: Sorafenib:” NCT01687673 ↗ “sorafenib” NCT01445080 ↗ “Sorafenib” NCT01703910 ↗ |
| Known as | Bay 43-9006, Sorafenib (Nexavar) | “Bay 43-9006, Sorafenib (Nexavar®)” NCT01906216 ↗ |
| Known as | BAY 43-906 | “Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days.” NCT00110344 ↗ |
| Known as | BAY43-9006 | “The purpose of this study is to test the combination of radiation treatment and an anti-angiogenic drug called sorafenib (or BAY 43-9006 or Nexavar) to determine the effects of...” NCT00610246 ↗81“This report describes the U.S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for...” PMID 17189398 ↗ Dec 2006 “Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose...” NCT00494299 ↗ “This is an investigational study. Sorafenib (BAY 43-9006) has been approved by the FDA for treatment of advanced renal cell cancer; however, it's use in this research study is...” NCT00411671 ↗ “A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias” NCT01445080 ↗ “Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)” NCT00108953 ↗ “Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma” NCT00418496 ↗ “Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor with effects on tumor proliferation and tumor angiogenesis.” NCT01510756 ↗ “A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors” NCT00126620 ↗ “II. To assess objective response rate of sorafenib (BAY 43-9006) in sporadic metastatic medullary thyroid carcinoma.” NCT00390325 ↗ “Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature.” NCT00866320 ↗ “Sorafenib (BAY 43-9006), a novel bi-aryl urea, is a potent inhibitor of VEGFR2 and Raf kinase.” NCT00464919 ↗ “Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)” NCT00044512 ↗ “daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)” NCT00492297 ↗ “Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)” NCT00865709 ↗ “BAY 43-9006 (SORAFENIB) is a novel dual-action Raf kinase and VEGFR inhibitor” NCT00405210 ↗ “Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon” NCT00352859 ↗ “Sorafenib is also known as BAY 43-9006 and by the trade name Nexavar®.” NCT00837148 ↗ “BAY 43-9006 (Sorafenib, Nexavar®, NCI-Supplied Agent, NSC #724772)” NCT00093626 ↗ “Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)” NCT00941863 ↗ “Sorafenib (BAY43-9006) Film-coated tablet” NCT02538393 ↗ “Drug: Sorafenib (Nexavar, BAY43-9006)” NCT00492752 ↗ “Drug: Sorafenib (Nexavar, BAY43-9006)” NCT00984282 ↗ “Drug: Sorafenib (Nexavar, BAY43-9006)” NCT01234337 ↗ “Nexavar (BAY 43-9006) (Sorafenib)” NCT00727233 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00300885 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00829231 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00663741 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00618982 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00606125 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00791778 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00101400 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00101413 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00562523 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00901901 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT01069328 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00558636 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT01098760 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00110344 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00111020 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00622479 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00586495 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00661375 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00661180 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT02332031 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT01585870 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00492986 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00259129 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00079612 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00586105 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00105443 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00117637 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00625378 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00111007 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00562913 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00855218 ↗ “Sorafenib (BAY43-9006, Nexavar)” NCT00119639 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00110994 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00692770 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00863746 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00449033 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00657254 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00678288 ↗ “Sorafenib (Nexavar,BAY43-9006)” NCT02114658 ↗ “Oral Sorafenib (BAY43-9006)” NCT00522301 ↗ “Sorafenib (Bay 43-9006)” NCT00619541 ↗ “Sorafenib (BAY-43-9006)” NCT00490685 ↗ “Sorafenib (BAY-43-9006)” NCT00406601 ↗ “Sorafenib (BAY-43-9006)” NCT06972641 ↗ “Sorafenib (BAY 43-9006)” NCT00483301 ↗ “Sorafenib (BAY43-9006)” NCT01915602 ↗ “Sorafenib (BAY43-9006)” NCT00542971 ↗ |
| Known as | mesylate sorafenib | “mesylate sorafenib, 400 mg, oral twice a day, continuous oral” NCT04518852 ↗ |
| Known as | Nevaxar | “treatment with Sorafenib (Nevaxar) in patients with hepatocellular carcinoma” NCT02867280 ↗ |
| Known as | NEX | “the aim of the present NEXIRI-2/PRODIGE 27 trial was to assess the 2-month non-progression rate for sorafenib (NEX) plus irinotecan (IRI), that is, NEXIRI, treatment.” PMID 32737004 ↗ May 2020 |
| Known as | Nexavar | “Exploratory Open Label Dose-escalation Phase Ib Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO5323441, Administered Intravenously, in Combination...” NCT01308723 ↗79“The purpose of this study is to test the combination of radiation treatment and an anti-angiogenic drug called sorafenib (or BAY 43-9006 or Nexavar) to determine the effects of...” NCT00610246 ↗ “This report describes the U.S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for...” PMID 17189398 ↗ Dec 2006 “Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose...” NCT00494299 ↗ “Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food...” NCT01170104 ↗ “Subjects are invited to participate in this study that will examine the use of three drugs called Sorafenib (Nexavar), Vorinostat (Zolinza) and Bortezomib (Velcade) for...” NCT01534260 ↗ “Randomized Phase II Trial Assessing the Combination of Nexavar® (Sorafenib), and Gemcitabine/Oxaliplatin in Patients Treated for Advanced (Unresectable/Metastatic)...” NCT00941967 ↗ “The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured...” NCT01348503 ↗ “To evaluate the efficacy and safety of a combined treatment with Sorafenib (Nexavar®) and pegylated interferon-α-2b (PegIntron®) in patients with malignant melanoma in stage IV.” NCT00623402 ↗ “A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma” NCT04000737 ↗ “Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)” NCT00108953 ↗ “Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals).” NCT01482442 ↗ “Sorafenib is a new drug, which is approved under the brand name Nexavar for the treatment of liver cancer.” NCT01849588 ↗ “Sorafenib (Nexavar) is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis” PMID 21342228 ↗ Nov 2010 “Sorafenib (NexavarTM) is designed to block the function of important proteins in cancer cells.” NCT00543504 ↗ “Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)” NCT00044512 ↗ “Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)” NCT00865709 ↗ “Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)” NCT01245582 ↗ “Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon” NCT00352859 ↗ “Sorafenib is also known as BAY 43-9006 and by the trade name Nexavar®.” NCT00837148 ↗ “sorafenib (Nexavar) in Subjects With Metastatic Renal Cell Carcinoma” NCT00389285 ↗ “Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor” NCT03406364 ↗ “Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)” NCT00941863 ↗ “Sorafenib (Nexavar®) and Capecitabine (Xeloda®)” NCT01032850 ↗ “a 200 mg Sorafenib (Nexavar®) reference tablet” NCT05967377 ↗ “Nexavar (Sorafenib) and irinotecan (Campto)” NCT00989469 ↗ “sorafenib (Nexavar®), thalidomide (Thado®)” NCT00971126 ↗ “Drug: Sorafenib (Nexavar, BAY43-9006)” NCT00492752 ↗ “Drug: Sorafenib (Nexavar, BAY43-9006)” NCT00984282 ↗ “Drug: Sorafenib (Nexavar, BAY43-9006)” NCT01234337 ↗ “Sorafenib is also known as Nexavar®.” NCT00917462 ↗ “Nexavar (BAY 43-9006) (Sorafenib)” NCT00727233 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00622479 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00663741 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00618982 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00606125 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00791778 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00101400 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00111007 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00101413 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00562523 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00300885 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT01069328 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00558636 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT02332031 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT01585870 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT01098760 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00829231 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00901901 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00492986 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00855218 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00678288 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00259129 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00079612 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00586105 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00117637 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00111020 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00625378 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00105443 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00586495 ↗ “Sorafenib (BAY43-9006, Nexavar)” NCT00119639 ↗ “Nexavar (Sorafenib, BAY43-9006)” NCT00692770 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00110994 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00863746 ↗ “Sorafenib (Nexavar, BAY43-9006)” NCT00449033 ↗ “Sorafenib (Nexavar,BAY43-9006)” NCT02114658 ↗ “Drug: sorafenib (Nexavar)” NCT00922584 ↗ “Drug: Nexavar (Sorafenib)” NCT00609401 ↗ “sorafenib (Nexavar®)” NCT00828594 ↗ “Sorafenib (Nexavar)” NCT01338857 ↗ “Nexavar (Sorafenib)” NCT00548899 ↗ “Sorafenib (Nexavar)” NCT00619996 ↗ “Sorafenib (Nexavar)” NCT00732914 ↗ “Nexavar” NCT01033240 ↗ |
| Known as | Nexavar (Sorafenib).ATC-Code: L01XE05 | “Nexavar (Sorafenib).ATC-Code: L01XE05” NCT00794235 ↗ |
| Known as | nexavar - sorafenib | “nexavar - sorafenib” NCT00808145 ↗4“Nexavar (Sorafenib)” NCT00801801 ↗ “Nexavar (sorafenib)” NCT01425216 ↗ “Nexavar (Sorafenib)” NCT00875745 ↗ “Nexavar (Sorafenib)” NCT00825734 ↗ |
| Known as | NSC# 724772 | “A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias” NCT01445080 ↗ |
| Known as | SFN | “SFN” NCT01075113 ↗ |
| Known as | SOR | “IMbrave150 is a phase III trial that assessed atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC) and...” PMID 34189869 ↗ Jun 20213“A phase 3, multinational, randomized, non-inferiority trial (REFLECT) compared the efficacy and safety of lenvatinib (LEN) and sorafenib (SOR) in patients with unresectable...” PMID 31720835 ↗ Nov 2019 “Everolimus (EVE) and sorafenib (SOR) combination was associated with synergistic activity in preclinical models.” PMID 36840749 ↗ Feb 2023 “Sorafenib (SOR)” NCT03037437 ↗ |
| Known as | SORA | “Sorafenib (SORA) was administered at 400mg twice daily on days 1 to 28.” NCT07264010 ↗ |
| Known as | Sorafenib (BAY 43-9006) | “Sorafenib (BAY 43-9006)” NCT00375310 ↗ |
| Known as | Sorafenib (Nexavar) | “Sorafenib (Nexavar®)” NCT01226056 ↗4“Sorafenib (Nexavar)” NCT01640665 ↗ “sorafenib (Nexavar)” NCT00844883 ↗ “sorafenib - Nexavar” NCT00780169 ↗ “sorafenib = nexavar” NCT01320111 ↗ |
| Known as | sorafenib tosylate | “PRIMARY OBJECTIVES:
I. To determine the pathologic response rate (\>= 95% necrosis) after preoperative treatment with sorafenib (sorafenib tosylate), epirubicin (epirubicin...” NCT02050919 ↗48“To compare the progression-free survival (PFS) rates of patients with desmoid tumors (DT)/deep fibromatosis (DF) who receive either sorafenib (sorafenib tosylate) or placebo...” NCT02066181 ↗ “To determine the objective response rate to sorafenib tosylate (sorafenib) in children with relapsed or refractory rhabdomyosarcoma, Wilms tumor, hepatocellular carcinoma...” NCT01502410 ↗ “To define a safe dose of sorafenib (sorafenib tosylate) to combine with riluzole in the treatment of patients with all types of solid tumors refractory to standard therapy or...” NCT01303341 ↗ “RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT00941967 ↗ “RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT01158287 ↗ “sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor” NCT01324076 ↗ “Patients receive oral erlotinib hydrochloride once daily and oral sorafenib tosylate twice daily on days 1-28.” NCT00801385 ↗ “Patients receive oral sorafenib tosylate twice daily on days 1-28 and bevacizumab IV on days 1 and 15.” NCT00867321 ↗ “I. Efficacy of BAY 43-9006 (sorafenib tosylate) by evaluating response rate.” NCT00126659 ↗ “Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.” NCT04344158 ↗ “Patients receive oral sorafenib tosylate and oral everolimus on days 1-28.” NCT00474929 ↗ “Sorafenib tosylate (400 mg, twice a day (BID), po)” NCT04985136 ↗ “sorafenib tosylate (sorafenib)” NCT01664182 ↗ “sorafenib tosylate (sorafenib)” NCT03211416 ↗ “Treatment (sorafenib tosylate)” NCT00096512 ↗ “Drug: sorafenib tosylate” NCT00098618 ↗ “Drug: sorafenib tosylate” NCT00245102 ↗ “Drug: sorafenib tosylate” NCT00098540 ↗ “Drug: sorafenib tosylate” NCT00134069 ↗ “Drug: sorafenib tosylate” NCT00278382 ↗ “Drug: Sorafenib Tosylate” NCT00126503 ↗ “Drug: sorafenib tosylate” NCT00126568 ↗ “Drug: sorafenib tosylate” NCT01005199 ↗ “Drug: sorafenib tosylate” NCT00131937 ↗ “Drug: sorafenib tosylate” NCT00182689 ↗ “Drug: sorafenib tosylate” NCT00217399 ↗ “Drug: Sorafenib Tosylate” NCT01445080 ↗ “Drug: Sorafenib Tosylate” NCT01253070 ↗ |
| Known as | Soranib Tablet | “Sorafenib (Soranib Tablet) will be administered orally at a dose of 600mg daily without food for patients who have been treated with prior systemic therapy for advanced HCC.” NCT05117957 ↗ |
| Known as | Suranix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01747642 ↗ |
| Action | Inhibit | “an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases” PMID 16908937 ↗ Aug 2006 |
| Modality | Small molecule | “This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases” PMID 16908937 ↗ Aug 2006 |
| Route | Oral | “received continuous, oral sorafenib 400 mg bid in 4-week cycles” PMID 16908937 ↗ Aug 2006 |
| Target | BRAF | “sorafenib is not an effective BRAF inhibitor” PMID 21206909 ↗ Dec 2010 |